Zobrazeno 1 - 10
of 559
pro vyhledávání: '"Alex A Adjei"'
Autor:
Kyungwha Lee, Jeeyun Lee, Mahesh Seetharam, Jae Lyun Lee, Jung-Yun Lee, Byoung Chul Cho, Myoung Ho Jang, Yujie Zhao, Nari Yun, Alex A Adjei, Chong Woo Park, Jian L Campian, Wen Wee Ma, Dongwoo Chae, Woosun Lee, Wooyul Lee, Sosun Park, Bochan Seo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/bade833e049342d5b94d87b5f5d30fab
Autor:
Xiaoyu Zhang, Anthony M Joshua, Sanjeev Kaul, Scott Antonia, Robert L Ferris, Roger B Cohen, Ezio Bonvini, Jan Baughman, Victoria Atkinson, Charu Aggarwal, Nicholas Vogelzang, Osama Rahma, Mahesh Seetharam, Yanyan Lou, Anthony Tolcher, Fernanda I Arnaldez, Amy Prawira, Ralph Hauke, Vinod Ganju, Andrew Weickhardt, Dan P Zandberg, Arash Rezazadeh Kalebasty, Alex A Adjei, Ariel Birnbaum, Rosetta Cavallo, Linda Peng, Paul A Moore, Stacie M Goldberg, Nehal J Lakhani
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/195a4377dadb4e879675192629df7c9e
Autor:
Jeremiah Stout, Cambray Smith, Jan Buckner, Alex A Adjei, Mark Wentworth, Jon C Tilburt, Zubin Master
Publikováno v:
PLoS ONE, Vol 16, Iss 12, p e0261478 (2021)
The U.S. Food and Drug Administration (FDA) allows patients with serious illnesses to access investigational drugs for "compassionate use" outside of clinical trials through expanded access (EA) Programs. The federal Right-to-Try Act created an addit
Externí odkaz:
https://doaj.org/article/e8ac8f53add34504ab1f6b3734d68c9c
Autor:
Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A Adjei, Jeffrey N Miner, Dominik Mumberg, Karl Ziegelbauer, Arne Scholz
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 10, Pp 1161-1171 (2013)
OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC)
Externí odkaz:
https://doaj.org/article/7b75d1b09ebc420588d3c375c24ac183
Publikováno v:
Journal of Thoracic Oncology. 18:143-157
Next-generation sequencing (NGS) technologies are high-throughput methods for DNA sequencing and have become a widely adopted tool in cancer research. The sheer amount and variety of data generated by NGS assays require sophisticated computational me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f941c60d7bf51fefc65bf99135275d08
https://doi.org/10.1016/j.jtho.2022.11.006
https://doi.org/10.1016/j.jtho.2022.11.006
Autor:
Emily Pei-Ying, Lin, Chih-Yuan, Hsu, Jeng-Fong, Chiou, Lynne, Berry, Leora, Horn, Paul, Bunn, James Chih-Hsin, Yang, Pan-Chyr, Yang, Alex A, Adjei, Yu, Shyr
Publikováno v:
Journal of Thoracic Oncology. 17:1365-1374
Survival benefit of immune checkpoint inhibitor (ICI) therapy in lung cancer is not fully understood.PubMed-cataloged publications through February 14, 2022, were queried for randomized controlled trials of ICI in lung cancer, and identified publicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2626756f1d39b8a240c3d624926ff3a
https://doi.org/10.1016/j.jtho.2022.08.010
https://doi.org/10.1016/j.jtho.2022.08.010
Autor:
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:7-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4ae99bafe70d07102f42b5929800257
https://doi.org/10.1007/s00280-022-04443-1
https://doi.org/10.1007/s00280-022-04443-1
Autor:
Alex A. Adjei, David E. Weng, Martin A. Graham, Myron Levin, Lainie P. Martin, Russell J. Schilder, Ravi K. Amaravadi
Supplemental Table S1. Patient disposition Supplemental Table S2. M30 and M65 for cohorts with greatest number of patients Supplemental Table S3. m65 fragment for cohort 1-3 Supplemental Table S4. caspase measurements
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ccfc218dcad0c17cf934c976884102
https://doi.org/10.1158/1535-7163.22506456
https://doi.org/10.1158/1535-7163.22506456
Autor:
Daniel J. Sargent, Richard M. Goldberg, Henry C. Pitot, Alex A. Adjei, Shauna L. Hillman, Megan E. Branda, Sumithra J. Mandrekar, Ming-Wen An
PDF file - 77KB, Table 1: Up to 16 Week Assessments adjusting for treatment arm and sum of baseline tumor measurements. Table 2: Up to 24 Week Assessments adjusting for treatment arm and sum of baseline tumor measurements.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d38852bf309a876b3ef7cb2a4aa128
https://doi.org/10.1158/1078-0432.22445196.v1
https://doi.org/10.1158/1078-0432.22445196.v1
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
Grade 3 or 4 adverse events possibly related to refametinib or sorafenib, occurring in {greater than or equal to}2 patients in either cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6739762d5f3f88061cfa4f75b3d7bb26
https://doi.org/10.1158/1078-0432.22459308
https://doi.org/10.1158/1078-0432.22459308